DFE Pharma Inhalation develops pharmaceutical lactose that facilitates delivery of your active ingredient to the lung. We work closely with pharmaceutical companies to design lactose particles with the required functionality for the drug, device and filling-platform. Our inhalation development team is available for customer's new product development.

DFE Pharma
Kleverstrasse 187
P.O. Box 20 21 20
Goch 47568
Germany

Phone+49 2823 9288 770
Websitewww.dfepharma.com
Emailpharma@dfepharma.com

Previous Conferences

Impact of Active Pharmaceutical Ingredient Span and the Amount of Lactose Fines on Dry Powder Inhaler Formulation Performance

Maria Bogalo Huescar, Harry Peters, Andy Burgess, Andrea Silvestri, Mohit R Mehta, Karin Marek
Respiratory Drug Delivery 2023: 201-204

Evaluation of the Impact of Polymorphic Forms of Lactose Having the Same Particle Size on Dry Powder Inhaler Aerodynamic Performance

Cigdem Acar, Pauline H Janssen, Lisa B Buijvoets, Ahat Koray
Respiratory Drug Delivery 2023: 443-448

Electrical Charge Measurements of Lactose Powder Blends Delivered from Dry Powder Inhaler Capsule Devices Using the BOLAR

Gerald A Hebbink, Guillermo Villarta, Harry Peters, Ville Niemelä, Esa Luntta
RDD Europe 2019: 235-240

Long Term Round Robin Results of a Particle Sizing Method of a Dry Powder Inhalation Carrier

David Stadermann, Mohit R Mehta, Gerald A Hebbink, Harry Peters
RDD Europe 2019: 241-246

Understanding the Influence of Device and Lactose Fines on Flow Properties and In Vitro Deposition from Dry Powder Inhalers

Mohit R Mehta, Kundan Pawar, Gerald A Hebbink, Hanne Kinnunen, Jagdeep Shur, Robert Price, Harry Peters
RDD Asia 2018: 193-198

All RDD Publications >>

↑ Back to Top